evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

470 questions · 477 findings · 110 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 68 · 14.3%GRADE not reported 41 · 8.6%Very low 143 · 30%Low 133 · 27.9%Moderate 73 · 15.3%High 19 · 4%

Intervention not reported

Adverse events requiring discontinuation of CSFs · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia

It is very uncertain whether the intervention changes adverse events requiring discontinuation of CSFs (very low certainty).

1 finding from 1 review

Febuxostat 80 mg/day vs placebo

Withdrawals due to adverse events · people with chronic gout

Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 120 mg/day vs placebo

Withdrawals due to adverse events · patients with chronic cout

Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 40 mg/day vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).

1 finding from 1 review

Febuxostat 80 mg/day vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (moderate certainty).

1 finding from 1 review

Febuxostat 120 mg/day vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).

1 finding from 1 review

Febuxostat 40 mg/day vs placebo

Withdrawals due to adverse events · people with chronic gout

Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Fluoroquinolones vs beta‐lactams

Discontinuation of medication due to adverse events · patients with Shigella dysentery

It is very uncertain whether fluoroquinolones changes adverse events leading to discontinuation of treatment compared with beta‐lactams (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Antipsychotic dose reduction vs dose continuation

Hospital readmission · patients with schizophrenia

It is very uncertain whether summary of findings table ‐ Antipsychotic dose reduction changes service use ‐ readmission to hospital (combined time points) compared with dose continuation (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Antipsychotic dose reduction vs dose continuation

Withdrawals due to adverse events · patients with schizophrenia

Summary of findings table ‐ Antipsychotic dose reduction probably leads to higher adverse effect ‐ leaving the study early due to adverse effects ‐… compared with dose continuation (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Antipsychotic dose reduction vs dose continuation

Global state ‐ number of participants with relapse/exacerbations of psychosis (combined time points) · patients with schizophrenia

Summary of findings table ‐ Antipsychotic dose reduction may leads to higher global state ‐ number of participants with relapse/exacerbations of… compared with dose continuation (low certainty).

1 finding from 1 review

Summary of findings table ‐ Antipsychotic dose reduction vs dose continuation

Leaving the study early ‐ for any reason ‐ overall acceptability (combined time points) · patients with schizophrenia

Summary of findings table ‐ Antipsychotic dose reduction probably leads to higher leaving the study early ‐ for any reason ‐ overall acceptability… compared with dose continuation (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Antipsychotic dose reduction vs dose continuation

Participants with at least some Side Effects · patients with schizophrenia

Summary of findings table ‐ Antipsychotic dose reduction showed no clear difference in adverse effects ‐ number of participants with at least 1 adverse… compared with dose continuation (moderate certainty).

1 finding from 1 review